| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors
|
Shimizu, Toshio
|
|
2016
|
77 |
5 |
p. 997-1003
|
artikel
|
| 2 |
Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor
|
Ogasawara, Masahito
|
|
2016
|
77 |
5 |
p. 1019-1029
|
artikel
|
| 3 |
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle
|
Burris, Howard A.
|
|
2016
|
77 |
5 |
p. 1079-1086
|
artikel
|
| 4 |
A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer
|
Kontopodis, E.
|
|
2016
|
77 |
5 |
p. 949-956
|
artikel
|
| 5 |
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
|
Kataoka, Hiromi
|
|
2016
|
77 |
5 |
p. 957-962
|
artikel
|
| 6 |
Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy
|
Groselj, Ales
|
|
2016
|
77 |
5 |
p. 939-947
|
artikel
|
| 7 |
Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer
|
Karayama, Masato
|
|
2016
|
77 |
5 |
p. 1011-1018
|
artikel
|
| 8 |
Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes
|
Zhang, Jingya
|
|
2016
|
77 |
5 |
p. 905-926
|
artikel
|
| 9 |
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience
|
Kudo, Kenichiro
|
|
2016
|
77 |
5 |
p. 1005-1009
|
artikel
|
| 10 |
Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer
|
Ozawa, Yuichi
|
|
2016
|
77 |
5 |
p. 1031-1038
|
artikel
|
| 11 |
Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy
|
Goldschmidt, Neta
|
|
2016
|
77 |
5 |
p. 1053-1060
|
artikel
|
| 12 |
Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation
|
Zhao, Fei
|
|
2016
|
77 |
5 |
p. 963-972
|
artikel
|
| 13 |
Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
|
Farhat, Fadi
|
|
2016
|
77 |
5 |
p. 1069-1077
|
artikel
|
| 14 |
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer
|
Said, Rabih
|
|
2016
|
77 |
5 |
p. 1097-1102
|
artikel
|
| 15 |
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
|
Khawaja, Muhammad R.
|
|
2016
|
77 |
5 |
p. 973-977
|
artikel
|
| 16 |
Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors
|
Yoshiba, Satoshi
|
|
2016
|
77 |
5 |
p. 987-996
|
artikel
|
| 17 |
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data
|
Wendling, Thierry
|
|
2016
|
77 |
5 |
p. 927-938
|
artikel
|
| 18 |
Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma
|
Kim, Young Saing
|
|
2016
|
77 |
5 |
p. 979-985
|
artikel
|
| 19 |
Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer
|
Shang, Chao
|
|
2016
|
77 |
5 |
p. 1061-1067
|
artikel
|
| 20 |
Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice
|
Edginton, Andrea N.
|
|
2016
|
77 |
5 |
p. 1039-1052
|
artikel
|
| 21 |
The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells
|
Shang, Fei
|
|
2016
|
77 |
5 |
p. 1087-1096
|
artikel
|
| 22 |
The druggability of intracellular nucleotide-degrading enzymes
|
Rampazzo, Chiara
|
|
2015
|
77 |
5 |
p. 883-893
|
artikel
|
| 23 |
The selective estrogen receptor modulators in breast cancer prevention
|
Li, Fangxuan
|
|
2016
|
77 |
5 |
p. 895-903
|
artikel
|
Tijdschrift beschrijving